The Prevalence and Clinical Significance of Iga Anti-Phosphatidylserine/ Prothrombin Antibodies in Systemic Autoimmune DiseasesPolona Žigon1*, Aleš Ambrožič1, Polonca Mali2, Matija Tomšič1, Snežna Sodin Šemrl1,3 and Saša Čučnik1,4
- *Corresponding Author:
- Polona Žigon
Department of Rheumatology
University Medical Centre, Ljubljana, Slovenia
Tel: +386 1 522 54 79
Email: [email protected]
Received Date: January 05, 2017; Accepted Date: February 10, 2017; Published Date: February 17, 2017
Citation: Žigon P, Ambrožic A, Mali P, Tomšic M, Šemrl SS, et al. (2017) The Prevalence and Clinical Significance of Iga Anti-Phosphatidylserine/Prothrombin Antibodies in Systemic Autoimmune Diseases. Immunome Res 13:130. doi: 10.4172/1745-7580.1000130
Copyright: © 2017 Žigon P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: Studies on antiphospholipid antibodies have mainly focused on the IgG and IgM isotypes, with only a few investigating the pathogenic significance of IgA antiphospholipid antibodies. Positive IgA anticardiolipin (aCL) and IgA anti-β2 glycoprotein I (anti-β2GPI) were reported to be predominantly associated with other antiphospholipid antibodies, making it difficult to understand the role of IgA alone. Recently, antibodies against phosphatidylserine/ prothrombin (aPS/PT) IgG and IgM have been indicated as a potential marker for antiphospholipid syndrome (APS). Our previous study reported that IgG and IgM aPS/PT showed highest association with lupus anticoagulant (LA) activity of all tested antiphospholipid antibodies, while no studies to date have investigated possible clinical benefits of IgA aPS/PT. In this study, we determined the prevalence of IgA aPS/PT in patients with systemic autoimmune diseases and evaluated their clinical association to thrombosis and obstetric complications. Methods: 254 patients with systemic autoimmune diseases were screened for LA, aCL, anti-β2GPI and aPS/PT (for IgG, IgM, IgA isotypes). Results: An overall prevalence of 63/254 (25%) was found for IgA aPS/PT in our cohort of patients. IgA aPS/PT were statistically significantly associated to LA activity and to both arterial and venous thrombosis, however no association was found to obstetric complications. Median levels of IgA aPS/PT were significantly higher in APS patients than in the non-APS patient control group comprising systemic lupus erythematosus, rheumatoid arthritis and Sjogren’s syndrome patients. Conclusion: Although IgA aPS/PT were predominantly associated with other antiphospholipid antibodies this study first confirmed their presence in APS patient samples and also showed a clear association of IgA aPS/PT to thrombosis and LA activity.